A Phase IIb trial testing monthly repeated nebulization of a lipid:CFTR complex stabilized lung function over the course of 1 year (Alton et al., 2015), demonstrating one of the most meaningful outcomes to date as CF patient lung function declines at ∼1–2% per year (Leung et al., 2020). The gene discussed is CFTR; the disease is cystic fibrosis.